Reshma Kewalramani - 19 Aug 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
19 Aug 2021
Transactions value $
$1,956,492
Form type
4
Filing time
23 Aug 2021, 08:30:57 UTC
Next filing
20 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Purchase $1.12M +5.76K +9.03% $195.14 69.5K 19 Aug 2021 Direct F1, F2
transaction VRTX Common Stock Purchase $833K +4.24K +6.1% $196.34 73.8K 19 Aug 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Open market purchases reported on this line occurred at a weighted average price of $195.14 (range $194.63 to $195.50).
F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
F3 Open market purchases reported on this line occurred at a weighted average price of $196.34 (range $195.74 to $196.58).